Aktie A3D7BL DERMATA THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Dermata Therapeutics, Inc.

Aktien

A3D7BL

US2498453065

DRMA

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 26.04.2024 		% 5 Tage % 1. Jan.
0.3427 USD +0.76% Intraday Chart für Dermata Therapeutics, Inc. +6.73% -43.82%
21.03. Dermata Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
05.01. Wall Street eröffnet schwächer als erwartet, da die monatlichen Arbeitsmarktdaten viel stärker als erwartet ausfielen MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Dermata Therapeutics : Provides Corporate Update and Reports Full Year 2023 Financial Results - Form 8-K
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Dermata to Present at the Emerging Growth Conference on February 7, 2024
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket
Top Premarket Gainers
North American Morning Briefing : Bond Yields Rise Again as Jobs Data Loom
Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon
Dermata Therapeutics to Begin Enrolling Patients in Acne Drug Study; To Raise $2.3 Million
Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Dermata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne
Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis
Dermata Therapeutics Completes $1.8 Million Share Offering
DERMATA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Certain Warrants of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.
Certain Common Stock of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D7BL Aktie
  4. Nachrichten Dermata Therapeutics, Inc.
  5. Andere Sprachen